nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—CYP3A4—breast cancer	0.132	0.546	CbGaD
Ergotamine—ABCB1—breast cancer	0.11	0.454	CbGaD
Ergotamine—HTR2B—Raloxifene—breast cancer	0.0781	0.159	CbGbCtD
Ergotamine—CYP1A2—Anastrozole—breast cancer	0.0366	0.0745	CbGbCtD
Ergotamine—CYP1A2—Toremifene—breast cancer	0.0335	0.0681	CbGbCtD
Ergotamine—ABCB1—Toremifene—breast cancer	0.0293	0.0596	CbGbCtD
Ergotamine—CYP3A4—Exemestane—breast cancer	0.0253	0.0515	CbGbCtD
Ergotamine—CYP3A4—Letrozole—breast cancer	0.0215	0.0438	CbGbCtD
Ergotamine—ABCB1—Lapatinib—breast cancer	0.0213	0.0435	CbGbCtD
Ergotamine—CYP3A4—Anastrozole—breast cancer	0.0192	0.039	CbGbCtD
Ergotamine—CYP3A4—Toremifene—breast cancer	0.0175	0.0357	CbGbCtD
Ergotamine—CYP3A4—Fulvestrant—breast cancer	0.0163	0.0332	CbGbCtD
Ergotamine—CYP3A4—Thiotepa—breast cancer	0.0145	0.0296	CbGbCtD
Ergotamine—CYP3A4—Ixabepilone—breast cancer	0.0133	0.027	CbGbCtD
Ergotamine—CYP3A4—Lapatinib—breast cancer	0.0128	0.026	CbGbCtD
Ergotamine—CYP1A2—Tamoxifen—breast cancer	0.0122	0.0249	CbGbCtD
Ergotamine—ABCB1—Vinorelbine—breast cancer	0.0118	0.0241	CbGbCtD
Ergotamine—ABCB1—Tamoxifen—breast cancer	0.0107	0.0218	CbGbCtD
Ergotamine—ABCB1—Mitoxantrone—breast cancer	0.0104	0.0212	CbGbCtD
Ergotamine—CYP3A4—Raloxifene—breast cancer	0.00969	0.0197	CbGbCtD
Ergotamine—ABCB1—Gemcitabine—breast cancer	0.00921	0.0187	CbGbCtD
Ergotamine—CYP1A2—Fluorouracil—breast cancer	0.00901	0.0183	CbGbCtD
Ergotamine—ABCB1—Paclitaxel—breast cancer	0.00832	0.0169	CbGbCtD
Ergotamine—ABCB1—Irinotecan—breast cancer	0.00821	0.0167	CbGbCtD
Ergotamine—ABCB1—Vinblastine—breast cancer	0.0073	0.0149	CbGbCtD
Ergotamine—CYP3A4—Vinorelbine—breast cancer	0.00709	0.0144	CbGbCtD
Ergotamine—CYP3A4—Tamoxifen—breast cancer	0.0064	0.013	CbGbCtD
Ergotamine—CYP3A4—Mitoxantrone—breast cancer	0.00624	0.0127	CbGbCtD
Ergotamine—ABCB1—Docetaxel—breast cancer	0.00601	0.0122	CbGbCtD
Ergotamine—CYP3A4—Paclitaxel—breast cancer	0.00498	0.0101	CbGbCtD
Ergotamine—CYP3A4—Irinotecan—breast cancer	0.00492	0.01	CbGbCtD
Ergotamine—ABCB1—Doxorubicin—breast cancer	0.00448	0.00913	CbGbCtD
Ergotamine—CYP3A4—Vinblastine—breast cancer	0.00437	0.0089	CbGbCtD
Ergotamine—ABCB1—Methotrexate—breast cancer	0.00434	0.00884	CbGbCtD
Ergotamine—CYP3A4—Docetaxel—breast cancer	0.0036	0.00734	CbGbCtD
Ergotamine—CYP3A4—Doxorubicin—breast cancer	0.00269	0.00547	CbGbCtD
Ergotamine—Sensory loss—Vinorelbine—breast cancer	0.00114	0.0092	CcSEcCtD
Ergotamine—Paraesthesia—Fluoxymesterone—breast cancer	0.00108	0.00866	CcSEcCtD
Ergotamine—Hypoaesthesia—Exemestane—breast cancer	0.000953	0.00766	CcSEcCtD
Ergotamine—Numbness—Fluorouracil—breast cancer	0.000945	0.0076	CcSEcCtD
Ergotamine—Sensory loss—Fluorouracil—breast cancer	0.000904	0.00727	CcSEcCtD
Ergotamine—Hypoaesthesia—Ixabepilone—breast cancer	0.000899	0.00723	CcSEcCtD
Ergotamine—Myalgia—Lapatinib—breast cancer	0.000888	0.00714	CcSEcCtD
Ergotamine—Vertigo—Fulvestrant—breast cancer	0.000862	0.00693	CcSEcCtD
Ergotamine—Vertigo—Toremifene—breast cancer	0.000851	0.00684	CcSEcCtD
Ergotamine—Hypoaesthesia—Letrozole—breast cancer	0.000846	0.0068	CcSEcCtD
Ergotamine—Myalgia—Fulvestrant—breast cancer	0.000817	0.00657	CcSEcCtD
Ergotamine—Hypoaesthesia—Raloxifene—breast cancer	0.000803	0.00646	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Lapatinib—breast cancer	0.000776	0.00624	CcSEcCtD
Ergotamine—Pain—Carboplatin—breast cancer	0.000772	0.00621	CcSEcCtD
Ergotamine—Sensory loss—Paclitaxel—breast cancer	0.00077	0.00619	CcSEcCtD
Ergotamine—Hypertension—Exemestane—breast cancer	0.00072	0.00578	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Fulvestrant—breast cancer	0.000714	0.00574	CcSEcCtD
Ergotamine—Nausea—Fluoxymesterone—breast cancer	0.000713	0.00573	CcSEcCtD
Ergotamine—Myalgia—Exemestane—breast cancer	0.00071	0.0057	CcSEcCtD
Ergotamine—Paraesthesia—Fulvestrant—breast cancer	0.000703	0.00565	CcSEcCtD
Ergotamine—Pain—Fulvestrant—breast cancer	0.00067	0.00538	CcSEcCtD
Ergotamine—Myalgia—Ixabepilone—breast cancer	0.00067	0.00538	CcSEcCtD
Ergotamine—Vertigo—Letrozole—breast cancer	0.000665	0.00535	CcSEcCtD
Ergotamine—Pain—Toremifene—breast cancer	0.000661	0.00531	CcSEcCtD
Ergotamine—Hypertension—Anastrozole—breast cancer	0.000639	0.00514	CcSEcCtD
Ergotamine—Hypertension—Letrozole—breast cancer	0.000639	0.00514	CcSEcCtD
Ergotamine—Vertigo—Raloxifene—breast cancer	0.000632	0.00508	CcSEcCtD
Ergotamine—Myalgia—Anastrozole—breast cancer	0.000631	0.00507	CcSEcCtD
Ergotamine—Myalgia—Letrozole—breast cancer	0.000631	0.00507	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Exemestane—breast cancer	0.00062	0.00498	CcSEcCtD
Ergotamine—Asthenia—Lapatinib—breast cancer	0.000611	0.00491	CcSEcCtD
Ergotamine—Paraesthesia—Exemestane—breast cancer	0.000611	0.00491	CcSEcCtD
Ergotamine—Pruritus—Lapatinib—breast cancer	0.000602	0.00484	CcSEcCtD
Ergotamine—Myalgia—Raloxifene—breast cancer	0.000598	0.00481	CcSEcCtD
Ergotamine—Hypoaesthesia—Vinblastine—breast cancer	0.000596	0.00479	CcSEcCtD
Ergotamine—Tachycardia—Letrozole—breast cancer	0.00059	0.00474	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Ixabepilone—breast cancer	0.000585	0.0047	CcSEcCtD
Ergotamine—Pain—Exemestane—breast cancer	0.000582	0.00468	CcSEcCtD
Ergotamine—Hypoaesthesia—Tamoxifen—breast cancer	0.000579	0.00466	CcSEcCtD
Ergotamine—Paraesthesia—Ixabepilone—breast cancer	0.000576	0.00463	CcSEcCtD
Ergotamine—Cyanosis—Methotrexate—breast cancer	0.000576	0.00463	CcSEcCtD
Ergotamine—Asthenia—Fulvestrant—breast cancer	0.000562	0.00452	CcSEcCtD
Ergotamine—Asthenia—Toremifene—breast cancer	0.000555	0.00446	CcSEcCtD
Ergotamine—Pruritus—Fulvestrant—breast cancer	0.000554	0.00445	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Anastrozole—breast cancer	0.000551	0.00443	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Letrozole—breast cancer	0.000551	0.00443	CcSEcCtD
Ergotamine—Pain—Ixabepilone—breast cancer	0.000549	0.00441	CcSEcCtD
Ergotamine—Pruritus—Toremifene—breast cancer	0.000547	0.0044	CcSEcCtD
Ergotamine—Paraesthesia—Letrozole—breast cancer	0.000543	0.00436	CcSEcCtD
Ergotamine—Paraesthesia—Anastrozole—breast cancer	0.000543	0.00436	CcSEcCtD
Ergotamine—Vomiting—Lapatinib—breast cancer	0.000541	0.00435	CcSEcCtD
Ergotamine—Ergoloid mesylate—CYP3A4—breast cancer	0.000526	0.171	CrCbGaD
Ergotamine—Musculoskeletal discomfort—Raloxifene—breast cancer	0.000523	0.0042	CcSEcCtD
Ergotamine—Pain—Anastrozole—breast cancer	0.000517	0.00416	CcSEcCtD
Ergotamine—Pain—Letrozole—breast cancer	0.000517	0.00416	CcSEcCtD
Ergotamine—Nausea—Lapatinib—breast cancer	0.000506	0.00407	CcSEcCtD
Ergotamine—HTR1E—female gonad—breast cancer	0.000506	0.0467	CbGeAlD
Ergotamine—Vomiting—Fulvestrant—breast cancer	0.000498	0.004	CcSEcCtD
Ergotamine—Hypoaesthesia—Vinorelbine—breast cancer	0.000496	0.00398	CcSEcCtD
Ergotamine—Vomiting—Toremifene—breast cancer	0.000491	0.00395	CcSEcCtD
Ergotamine—Pain—Raloxifene—breast cancer	0.000491	0.00394	CcSEcCtD
Ergotamine—Asthenia—Exemestane—breast cancer	0.000488	0.00392	CcSEcCtD
Ergotamine—Pruritus—Exemestane—breast cancer	0.000481	0.00387	CcSEcCtD
Ergotamine—Vertigo—Vinblastine—breast cancer	0.000469	0.00377	CcSEcCtD
Ergotamine—Nausea—Fulvestrant—breast cancer	0.000465	0.00374	CcSEcCtD
Ergotamine—Asthenia—Ixabepilone—breast cancer	0.000461	0.0037	CcSEcCtD
Ergotamine—Nausea—Toremifene—breast cancer	0.000459	0.00369	CcSEcCtD
Ergotamine—ADRA1D—epithelium—breast cancer	0.000458	0.0424	CbGeAlD
Ergotamine—Pruritus—Ixabepilone—breast cancer	0.000454	0.00365	CcSEcCtD
Ergotamine—Hypertension—Vinblastine—breast cancer	0.00045	0.00362	CcSEcCtD
Ergotamine—Hypertension—Tamoxifen—breast cancer	0.000438	0.00352	CcSEcCtD
Ergotamine—Asthenia—Anastrozole—breast cancer	0.000434	0.00349	CcSEcCtD
Ergotamine—Asthenia—Letrozole—breast cancer	0.000434	0.00349	CcSEcCtD
Ergotamine—Vomiting—Exemestane—breast cancer	0.000433	0.00348	CcSEcCtD
Ergotamine—Myalgia—Tamoxifen—breast cancer	0.000431	0.00347	CcSEcCtD
Ergotamine—Pruritus—Letrozole—breast cancer	0.000428	0.00344	CcSEcCtD
Ergotamine—Pruritus—Anastrozole—breast cancer	0.000428	0.00344	CcSEcCtD
Ergotamine—Myalgia—Melphalan—breast cancer	0.000422	0.0034	CcSEcCtD
Ergotamine—Bradycardia—Irinotecan—breast cancer	0.000418	0.00336	CcSEcCtD
Ergotamine—Bradycardia—Mitoxantrone—breast cancer	0.000418	0.00336	CcSEcCtD
Ergotamine—Hypertension—Goserelin—breast cancer	0.000418	0.00336	CcSEcCtD
Ergotamine—Myalgia—Goserelin—breast cancer	0.000412	0.00331	CcSEcCtD
Ergotamine—Vomiting—Ixabepilone—breast cancer	0.000408	0.00328	CcSEcCtD
Ergotamine—Nausea—Exemestane—breast cancer	0.000404	0.00325	CcSEcCtD
Ergotamine—Dihydroergotamine—CYP3A4—breast cancer	0.000399	0.13	CrCbGaD
Ergotamine—Pain—Chlorambucil—breast cancer	0.000397	0.00319	CcSEcCtD
Ergotamine—Tachycardia—Melphalan—breast cancer	0.000395	0.00318	CcSEcCtD
Ergotamine—Hypoaesthesia—Fluorouracil—breast cancer	0.000391	0.00315	CcSEcCtD
Ergotamine—Vertigo—Vinorelbine—breast cancer	0.00039	0.00313	CcSEcCtD
Ergotamine—Tachycardia—Goserelin—breast cancer	0.000386	0.0031	CcSEcCtD
Ergotamine—Vomiting—Letrozole—breast cancer	0.000384	0.00309	CcSEcCtD
Ergotamine—Vomiting—Anastrozole—breast cancer	0.000384	0.00309	CcSEcCtD
Ergotamine—Paraesthesia—Vinblastine—breast cancer	0.000382	0.00307	CcSEcCtD
Ergotamine—Nausea—Ixabepilone—breast cancer	0.000381	0.00306	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Tamoxifen—breast cancer	0.000377	0.00303	CcSEcCtD
Ergotamine—Hypertension—Vinorelbine—breast cancer	0.000374	0.00301	CcSEcCtD
Ergotamine—Paraesthesia—Tamoxifen—breast cancer	0.000371	0.00299	CcSEcCtD
Ergotamine—Myalgia—Vinorelbine—breast cancer	0.000369	0.00297	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Melphalan—breast cancer	0.000369	0.00297	CcSEcCtD
Ergotamine—Vomiting—Idarubicin—breast cancer	0.000365	0.00293	CcSEcCtD
Ergotamine—Vomiting—Raloxifene—breast cancer	0.000365	0.00293	CcSEcCtD
Ergotamine—Ergonovine—CYP3A4—breast cancer	0.000365	0.119	CrCbGaD
Ergotamine—Pain—Vinblastine—breast cancer	0.000364	0.00293	CcSEcCtD
Ergotamine—Paraesthesia—Melphalan—breast cancer	0.000364	0.00292	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Goserelin—breast cancer	0.00036	0.00289	CcSEcCtD
Ergotamine—Nausea—Anastrozole—breast cancer	0.000359	0.00289	CcSEcCtD
Ergotamine—Nausea—Letrozole—breast cancer	0.000359	0.00289	CcSEcCtD
Ergotamine—Hypertension—Thiotepa—breast cancer	0.000357	0.00287	CcSEcCtD
Ergotamine—Paraesthesia—Goserelin—breast cancer	0.000355	0.00285	CcSEcCtD
Ergotamine—Pain—Tamoxifen—breast cancer	0.000354	0.00284	CcSEcCtD
Ergotamine—Myalgia—Thiotepa—breast cancer	0.000352	0.00283	CcSEcCtD
Ergotamine—Pain—Melphalan—breast cancer	0.000346	0.00278	CcSEcCtD
Ergotamine—Tachycardia—Vinorelbine—breast cancer	0.000345	0.00278	CcSEcCtD
Ergotamine—Bradycardia—Paclitaxel—breast cancer	0.000341	0.00274	CcSEcCtD
Ergotamine—Nausea—Raloxifene—breast cancer	0.000341	0.00274	CcSEcCtD
Ergotamine—Nausea—Idarubicin—breast cancer	0.000341	0.00274	CcSEcCtD
Ergotamine—ADRA1D—female reproductive system—breast cancer	0.000341	0.0315	CbGeAlD
Ergotamine—Pain—Goserelin—breast cancer	0.000338	0.00272	CcSEcCtD
Ergotamine—Asthenia—Chlorambucil—breast cancer	0.000333	0.00268	CcSEcCtD
Ergotamine—Hypoaesthesia—Paclitaxel—breast cancer	0.000333	0.00268	CcSEcCtD
Ergotamine—Dihydroergotamine—ABCB1—breast cancer	0.000332	0.108	CrCbGaD
Ergotamine—Tachycardia—Thiotepa—breast cancer	0.00033	0.00265	CcSEcCtD
Ergotamine—Pruritus—Chlorambucil—breast cancer	0.000329	0.00264	CcSEcCtD
Ergotamine—CYP1A2—nipple—breast cancer	0.000323	0.0299	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Vinorelbine—breast cancer	0.000322	0.00259	CcSEcCtD
Ergotamine—Vertigo—Irinotecan—breast cancer	0.000321	0.00258	CcSEcCtD
Ergotamine—Methylergometrine—CYP3A4—breast cancer	0.000319	0.104	CrCbGaD
Ergotamine—Paraesthesia—Vinorelbine—breast cancer	0.000318	0.00255	CcSEcCtD
Ergotamine—Hypertension—Irinotecan—breast cancer	0.000309	0.00248	CcSEcCtD
Ergotamine—Hypertension—Mitoxantrone—breast cancer	0.000309	0.00248	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Thiotepa—breast cancer	0.000308	0.00247	CcSEcCtD
Ergotamine—Asthenia—Vinblastine—breast cancer	0.000305	0.00246	CcSEcCtD
Ergotamine—Myalgia—Mitoxantrone—breast cancer	0.000304	0.00245	CcSEcCtD
Ergotamine—Ergonovine—ABCB1—breast cancer	0.000303	0.0989	CrCbGaD
Ergotamine—Paraesthesia—Thiotepa—breast cancer	0.000303	0.00244	CcSEcCtD
Ergotamine—HTR2B—skin of body—breast cancer	0.000303	0.028	CbGeAlD
Ergotamine—Pain—Vinorelbine—breast cancer	0.000303	0.00243	CcSEcCtD
Ergotamine—Hypertension—Gemcitabine—breast cancer	0.000301	0.00242	CcSEcCtD
Ergotamine—ADRA2A—nipple—breast cancer	0.000297	0.0275	CbGeAlD
Ergotamine—Asthenia—Tamoxifen—breast cancer	0.000297	0.00239	CcSEcCtD
Ergotamine—Myalgia—Gemcitabine—breast cancer	0.000297	0.00238	CcSEcCtD
Ergotamine—Vomiting—Chlorambucil—breast cancer	0.000295	0.00237	CcSEcCtD
Ergotamine—Pruritus—Tamoxifen—breast cancer	0.000293	0.00235	CcSEcCtD
Ergotamine—Myalgia—Fluorouracil—breast cancer	0.000292	0.00234	CcSEcCtD
Ergotamine—Asthenia—Melphalan—breast cancer	0.000291	0.00234	CcSEcCtD
Ergotamine—Pain—Thiotepa—breast cancer	0.000289	0.00232	CcSEcCtD
Ergotamine—ADRA1D—endocrine gland—breast cancer	0.000288	0.0266	CbGeAlD
Ergotamine—Pruritus—Melphalan—breast cancer	0.000287	0.0023	CcSEcCtD
Ergotamine—HTR2B—endometrium—breast cancer	0.000286	0.0264	CbGeAlD
Ergotamine—Tachycardia—Mitoxantrone—breast cancer	0.000285	0.00229	CcSEcCtD
Ergotamine—Asthenia—Goserelin—breast cancer	0.000283	0.00228	CcSEcCtD
Ergotamine—Hypoaesthesia—Docetaxel—breast cancer	0.000283	0.00227	CcSEcCtD
Ergotamine—Bradycardia—Capecitabine—breast cancer	0.00028	0.00225	CcSEcCtD
Ergotamine—Pruritus—Goserelin—breast cancer	0.00028	0.00225	CcSEcCtD
Ergotamine—Nausea—Chlorambucil—breast cancer	0.000276	0.00222	CcSEcCtD
Ergotamine—Hypoaesthesia—Capecitabine—breast cancer	0.000274	0.0022	CcSEcCtD
Ergotamine—Tachycardia—Fluorouracil—breast cancer	0.000273	0.00219	CcSEcCtD
Ergotamine—Vomiting—Vinblastine—breast cancer	0.000271	0.00218	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Mitoxantrone—breast cancer	0.000266	0.00214	CcSEcCtD
Ergotamine—HTR2B—uterus—breast cancer	0.000263	0.0243	CbGeAlD
Ergotamine—ADRA1A—epithelium—breast cancer	0.000263	0.0243	CbGeAlD
Ergotamine—Vomiting—Tamoxifen—breast cancer	0.000263	0.00211	CcSEcCtD
Ergotamine—HTR1B—female reproductive system—breast cancer	0.000263	0.0243	CbGeAlD
Ergotamine—Paraesthesia—Mitoxantrone—breast cancer	0.000262	0.00211	CcSEcCtD
Ergotamine—Paraesthesia—Irinotecan—breast cancer	0.000262	0.00211	CcSEcCtD
Ergotamine—Vertigo—Paclitaxel—breast cancer	0.000262	0.00211	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Gemcitabine—breast cancer	0.000259	0.00208	CcSEcCtD
Ergotamine—HTR2B—adipose tissue—breast cancer	0.000258	0.0238	CbGeAlD
Ergotamine—Vomiting—Melphalan—breast cancer	0.000258	0.00207	CcSEcCtD
Ergotamine—Paraesthesia—Gemcitabine—breast cancer	0.000255	0.00205	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Fluorouracil—breast cancer	0.000255	0.00205	CcSEcCtD
Ergotamine—HTR1D—female reproductive system—breast cancer	0.000255	0.0235	CbGeAlD
Ergotamine—Asthenia—Vinorelbine—breast cancer	0.000254	0.00204	CcSEcCtD
Ergotamine—Nausea—Vinblastine—breast cancer	0.000253	0.00203	CcSEcCtD
Ergotamine—HTR2C—female reproductive system—breast cancer	0.000252	0.0233	CbGeAlD
Ergotamine—Hypertension—Paclitaxel—breast cancer	0.000252	0.00202	CcSEcCtD
Ergotamine—Vomiting—Goserelin—breast cancer	0.000251	0.00202	CcSEcCtD
Ergotamine—Paraesthesia—Fluorouracil—breast cancer	0.000251	0.00202	CcSEcCtD
Ergotamine—Pruritus—Vinorelbine—breast cancer	0.00025	0.00201	CcSEcCtD
Ergotamine—Pain—Mitoxantrone—breast cancer	0.00025	0.00201	CcSEcCtD
Ergotamine—Pain—Irinotecan—breast cancer	0.00025	0.00201	CcSEcCtD
Ergotamine—Lisuride—CYP2D6—breast cancer	0.000249	0.0812	CrCbGaD
Ergotamine—Myalgia—Paclitaxel—breast cancer	0.000248	0.002	CcSEcCtD
Ergotamine—Nausea—Tamoxifen—breast cancer	0.000246	0.00198	CcSEcCtD
Ergotamine—Pain—Gemcitabine—breast cancer	0.000243	0.00195	CcSEcCtD
Ergotamine—Asthenia—Thiotepa—breast cancer	0.000242	0.00195	CcSEcCtD
Ergotamine—Nausea—Melphalan—breast cancer	0.000241	0.00193	CcSEcCtD
Ergotamine—Pruritus—Thiotepa—breast cancer	0.000239	0.00192	CcSEcCtD
Ergotamine—Pain—Fluorouracil—breast cancer	0.000239	0.00192	CcSEcCtD
Ergotamine—HTR2B—female reproductive system—breast cancer	0.000237	0.0219	CbGeAlD
Ergotamine—Nausea—Goserelin—breast cancer	0.000235	0.00189	CcSEcCtD
Ergotamine—Tachycardia—Paclitaxel—breast cancer	0.000232	0.00187	CcSEcCtD
Ergotamine—HTR2B—adrenal gland—breast cancer	0.000231	0.0214	CbGeAlD
Ergotamine—Vomiting—Vinorelbine—breast cancer	0.000225	0.00181	CcSEcCtD
Ergotamine—HTR1B—endocrine gland—breast cancer	0.000222	0.0206	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.000217	0.00174	CcSEcCtD
Ergotamine—Vertigo—Capecitabine—breast cancer	0.000215	0.00173	CcSEcCtD
Ergotamine—Vomiting—Thiotepa—breast cancer	0.000215	0.00173	CcSEcCtD
Ergotamine—Lisuride—CYP3A4—breast cancer	0.000214	0.0696	CrCbGaD
Ergotamine—Paraesthesia—Paclitaxel—breast cancer	0.000214	0.00172	CcSEcCtD
Ergotamine—Hypertension—Docetaxel—breast cancer	0.000213	0.00172	CcSEcCtD
Ergotamine—ADRA1A—adipose tissue—breast cancer	0.000213	0.0197	CbGeAlD
Ergotamine—Myalgia—Docetaxel—breast cancer	0.00021	0.00169	CcSEcCtD
Ergotamine—SLC6A2—female reproductive system—breast cancer	0.00021	0.0194	CbGeAlD
Ergotamine—Nausea—Vinorelbine—breast cancer	0.00021	0.00169	CcSEcCtD
Ergotamine—DRD2—pituitary gland—breast cancer	0.000209	0.0193	CbGeAlD
Ergotamine—Asthenia—Mitoxantrone—breast cancer	0.000209	0.00168	CcSEcCtD
Ergotamine—Asthenia—Irinotecan—breast cancer	0.000209	0.00168	CcSEcCtD
Ergotamine—HTR2A—embryo—breast cancer	0.000209	0.0193	CbGeAlD
Ergotamine—HTR1A—adrenal gland—breast cancer	0.000207	0.0191	CbGeAlD
Ergotamine—Hypertension—Capecitabine—breast cancer	0.000207	0.00166	CcSEcCtD
Ergotamine—SLC6A2—adrenal gland—breast cancer	0.000205	0.019	CbGeAlD
Ergotamine—Asthenia—Gemcitabine—breast cancer	0.000204	0.00164	CcSEcCtD
Ergotamine—Myalgia—Capecitabine—breast cancer	0.000204	0.00164	CcSEcCtD
Ergotamine—Pain—Paclitaxel—breast cancer	0.000204	0.00164	CcSEcCtD
Ergotamine—Pruritus—Gemcitabine—breast cancer	0.000201	0.00162	CcSEcCtD
Ergotamine—Nausea—Thiotepa—breast cancer	0.000201	0.00161	CcSEcCtD
Ergotamine—Bromocriptine—CYP3A4—breast cancer	0.000198	0.0645	CrCbGaD
Ergotamine—Pruritus—Fluorouracil—breast cancer	0.000198	0.00159	CcSEcCtD
Ergotamine—Tachycardia—Docetaxel—breast cancer	0.000197	0.00158	CcSEcCtD
Ergotamine—Bradycardia—Epirubicin—breast cancer	0.000195	0.00157	CcSEcCtD
Ergotamine—ADRA1A—adrenal gland—breast cancer	0.000191	0.0176	CbGeAlD
Ergotamine—Tachycardia—Capecitabine—breast cancer	0.000191	0.00153	CcSEcCtD
Ergotamine—Hypoaesthesia—Epirubicin—breast cancer	0.000191	0.00153	CcSEcCtD
Ergotamine—Vomiting—Irinotecan—breast cancer	0.000186	0.00149	CcSEcCtD
Ergotamine—Vomiting—Mitoxantrone—breast cancer	0.000186	0.00149	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000184	0.00148	CcSEcCtD
Ergotamine—Paraesthesia—Docetaxel—breast cancer	0.000181	0.00146	CcSEcCtD
Ergotamine—Vomiting—Gemcitabine—breast cancer	0.000181	0.00145	CcSEcCtD
Ergotamine—Bradycardia—Doxorubicin—breast cancer	0.00018	0.00145	CcSEcCtD
Ergotamine—HTR1A—endocrine gland—breast cancer	0.00018	0.0166	CbGeAlD
Ergotamine—ADRA2A—endometrium—breast cancer	0.00018	0.0166	CbGeAlD
Ergotamine—SLC6A2—endocrine gland—breast cancer	0.000178	0.0164	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000178	0.00143	CcSEcCtD
Ergotamine—Vomiting—Fluorouracil—breast cancer	0.000178	0.00143	CcSEcCtD
Ergotamine—Hypoaesthesia—Doxorubicin—breast cancer	0.000176	0.00142	CcSEcCtD
Ergotamine—Paraesthesia—Capecitabine—breast cancer	0.000175	0.00141	CcSEcCtD
Ergotamine—Nausea—Mitoxantrone—breast cancer	0.000173	0.00139	CcSEcCtD
Ergotamine—Nausea—Irinotecan—breast cancer	0.000173	0.00139	CcSEcCtD
Ergotamine—Pain—Docetaxel—breast cancer	0.000173	0.00139	CcSEcCtD
Ergotamine—Asthenia—Paclitaxel—breast cancer	0.000171	0.00137	CcSEcCtD
Ergotamine—HTR2A—epithelium—breast cancer	0.00017	0.0157	CbGeAlD
Ergotamine—Nausea—Gemcitabine—breast cancer	0.000169	0.00136	CcSEcCtD
Ergotamine—Pruritus—Paclitaxel—breast cancer	0.000168	0.00135	CcSEcCtD
Ergotamine—Pain—Capecitabine—breast cancer	0.000167	0.00134	CcSEcCtD
Ergotamine—Nausea—Fluorouracil—breast cancer	0.000166	0.00133	CcSEcCtD
Ergotamine—ADRA1A—endocrine gland—breast cancer	0.000165	0.0153	CbGeAlD
Ergotamine—ADRA2A—uterus—breast cancer	0.000165	0.0153	CbGeAlD
Ergotamine—Bromocriptine—ABCB1—breast cancer	0.000165	0.0537	CrCbGaD
Ergotamine—ADRA2A—pituitary gland—breast cancer	0.000162	0.015	CbGeAlD
Ergotamine—DRD2—endocrine gland—breast cancer	0.000162	0.015	CbGeAlD
Ergotamine—ADRA2A—adipose tissue—breast cancer	0.000162	0.0149	CbGeAlD
Ergotamine—Vertigo—Methotrexate—breast cancer	0.00016	0.00129	CcSEcCtD
Ergotamine—Myalgia—Methotrexate—breast cancer	0.000152	0.00122	CcSEcCtD
Ergotamine—Vomiting—Paclitaxel—breast cancer	0.000151	0.00122	CcSEcCtD
Ergotamine—Vertigo—Epirubicin—breast cancer	0.00015	0.0012	CcSEcCtD
Ergotamine—ADRA2A—female reproductive system—breast cancer	0.000149	0.0137	CbGeAlD
Ergotamine—ADRA2A—adrenal gland—breast cancer	0.000145	0.0134	CbGeAlD
Ergotamine—Asthenia—Docetaxel—breast cancer	0.000145	0.00116	CcSEcCtD
Ergotamine—Hypertension—Epirubicin—breast cancer	0.000144	0.00116	CcSEcCtD
Ergotamine—Pruritus—Docetaxel—breast cancer	0.000143	0.00115	CcSEcCtD
Ergotamine—Myalgia—Epirubicin—breast cancer	0.000142	0.00114	CcSEcCtD
Ergotamine—Nausea—Paclitaxel—breast cancer	0.000141	0.00114	CcSEcCtD
Ergotamine—Asthenia—Capecitabine—breast cancer	0.00014	0.00113	CcSEcCtD
Ergotamine—Vertigo—Doxorubicin—breast cancer	0.000139	0.00111	CcSEcCtD
Ergotamine—HTR2B—lymph node—breast cancer	0.000139	0.0128	CbGeAlD
Ergotamine—Pruritus—Capecitabine—breast cancer	0.000138	0.00111	CcSEcCtD
Ergotamine—HTR2A—pituitary gland—breast cancer	0.000138	0.0128	CbGeAlD
Ergotamine—CYP1A2—endocrine gland—breast cancer	0.000137	0.0126	CbGeAlD
Ergotamine—ABCB1—embryo—breast cancer	0.000137	0.0126	CbGeAlD
Ergotamine—ADRA2A—female gonad—breast cancer	0.000135	0.0125	CbGeAlD
Ergotamine—Hypertension—Doxorubicin—breast cancer	0.000133	0.00107	CcSEcCtD
Ergotamine—Tachycardia—Epirubicin—breast cancer	0.000133	0.00107	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methotrexate—breast cancer	0.000132	0.00106	CcSEcCtD
Ergotamine—Myalgia—Doxorubicin—breast cancer	0.000131	0.00106	CcSEcCtD
Ergotamine—Paraesthesia—Methotrexate—breast cancer	0.000131	0.00105	CcSEcCtD
Ergotamine—Vomiting—Docetaxel—breast cancer	0.000128	0.00103	CcSEcCtD
Ergotamine—HTR2A—female reproductive system—breast cancer	0.000126	0.0117	CbGeAlD
Ergotamine—ADRA2A—endocrine gland—breast cancer	0.000126	0.0116	CbGeAlD
Ergotamine—Pain—Methotrexate—breast cancer	0.000124	0.000999	CcSEcCtD
Ergotamine—Vomiting—Capecitabine—breast cancer	0.000124	0.000998	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Epirubicin—breast cancer	0.000124	0.000997	CcSEcCtD
Ergotamine—HTR2A—adrenal gland—breast cancer	0.000123	0.0114	CbGeAlD
Ergotamine—SLC6A2—lymph node—breast cancer	0.000123	0.0114	CbGeAlD
Ergotamine—Tachycardia—Doxorubicin—breast cancer	0.000123	0.000988	CcSEcCtD
Ergotamine—Paraesthesia—Epirubicin—breast cancer	0.000122	0.000982	CcSEcCtD
Ergotamine—Nausea—Docetaxel—breast cancer	0.00012	0.000963	CcSEcCtD
Ergotamine—CYP3A4—female reproductive system—breast cancer	0.000117	0.0108	CbGeAlD
Ergotamine—Pain—Epirubicin—breast cancer	0.000116	0.000935	CcSEcCtD
Ergotamine—Nausea—Capecitabine—breast cancer	0.000116	0.000933	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Doxorubicin—breast cancer	0.000115	0.000922	CcSEcCtD
Ergotamine—Paraesthesia—Doxorubicin—breast cancer	0.000113	0.000909	CcSEcCtD
Ergotamine—ABCB1—epithelium—breast cancer	0.000112	0.0103	CbGeAlD
Ergotamine—Pain—Doxorubicin—breast cancer	0.000108	0.000865	CcSEcCtD
Ergotamine—HTR2A—endocrine gland—breast cancer	0.000107	0.00989	CbGeAlD
Ergotamine—Asthenia—Methotrexate—breast cancer	0.000104	0.000839	CcSEcCtD
Ergotamine—Pruritus—Methotrexate—breast cancer	0.000103	0.000827	CcSEcCtD
Ergotamine—ABCB1—endometrium—breast cancer	0.0001	0.00924	CbGeAlD
Ergotamine—CYP3A4—endocrine gland—breast cancer	9.91e-05	0.00915	CbGeAlD
Ergotamine—Asthenia—Epirubicin—breast cancer	9.76e-05	0.000785	CcSEcCtD
Ergotamine—Pruritus—Epirubicin—breast cancer	9.63e-05	0.000774	CcSEcCtD
Ergotamine—Vomiting—Methotrexate—breast cancer	9.24e-05	0.000743	CcSEcCtD
Ergotamine—ABCB1—uterus—breast cancer	9.22e-05	0.00852	CbGeAlD
Ergotamine—ABCB1—pituitary gland—breast cancer	9.05e-05	0.00836	CbGeAlD
Ergotamine—Asthenia—Doxorubicin—breast cancer	9.03e-05	0.000726	CcSEcCtD
Ergotamine—ABCB1—adipose tissue—breast cancer	9.01e-05	0.00833	CbGeAlD
Ergotamine—Pruritus—Doxorubicin—breast cancer	8.91e-05	0.000716	CcSEcCtD
Ergotamine—ADRA2A—lymph node—breast cancer	8.7e-05	0.00804	CbGeAlD
Ergotamine—Vomiting—Epirubicin—breast cancer	8.65e-05	0.000695	CcSEcCtD
Ergotamine—Nausea—Methotrexate—breast cancer	8.64e-05	0.000694	CcSEcCtD
Ergotamine—ABCB1—female reproductive system—breast cancer	8.29e-05	0.00766	CbGeAlD
Ergotamine—ABCB1—adrenal gland—breast cancer	8.09e-05	0.00747	CbGeAlD
Ergotamine—Nausea—Epirubicin—breast cancer	8.08e-05	0.00065	CcSEcCtD
Ergotamine—Vomiting—Doxorubicin—breast cancer	8e-05	0.000643	CcSEcCtD
Ergotamine—ABCB1—bone marrow—breast cancer	7.82e-05	0.00723	CbGeAlD
Ergotamine—ABCB1—female gonad—breast cancer	7.54e-05	0.00697	CbGeAlD
Ergotamine—Nausea—Doxorubicin—breast cancer	7.48e-05	0.000601	CcSEcCtD
Ergotamine—ABCB1—endocrine gland—breast cancer	7.01e-05	0.00648	CbGeAlD
Ergotamine—ABCB1—lymph node—breast cancer	4.85e-05	0.00448	CbGeAlD
Ergotamine—CYP3A4—Metabolism—NCOA1—breast cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—breast cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—breast cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—breast cancer	2.48e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SRC—breast cancer	2.48e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—breast cancer	2.47e-06	1.92e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP19A1—breast cancer	2.47e-06	1.92e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—STK11—breast cancer	2.47e-06	1.92e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—breast cancer	2.47e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	2.47e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—breast cancer	2.46e-06	1.92e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1B—breast cancer	2.46e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—breast cancer	2.46e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TGFB1—breast cancer	2.46e-06	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—breast cancer	2.45e-06	1.9e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—breast cancer	2.44e-06	1.9e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—breast cancer	2.44e-06	1.9e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—breast cancer	2.43e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—breast cancer	2.43e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	2.42e-06	1.89e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1B—breast cancer	2.42e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—breast cancer	2.42e-06	1.88e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MDM2—breast cancer	2.41e-06	1.88e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—breast cancer	2.41e-06	1.88e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CASP3—breast cancer	2.41e-06	1.88e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK8—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RAF1—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—breast cancer	2.4e-06	1.87e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—breast cancer	2.4e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—breast cancer	2.4e-06	1.86e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RELA—breast cancer	2.4e-06	1.86e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SRC—breast cancer	2.4e-06	1.86e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—breast cancer	2.39e-06	1.86e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—breast cancer	2.39e-06	1.86e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SRC—breast cancer	2.38e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	2.38e-06	1.85e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CASP3—breast cancer	2.38e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	2.37e-06	1.85e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—breast cancer	2.37e-06	1.84e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—breast cancer	2.36e-06	1.84e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—breast cancer	2.36e-06	1.84e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—breast cancer	2.35e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MTOR—breast cancer	2.35e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	2.35e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	2.35e-06	1.83e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—JUN—breast cancer	2.34e-06	1.82e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—breast cancer	2.33e-06	1.81e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CTNNB1—breast cancer	2.33e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CASP3—breast cancer	2.33e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—breast cancer	2.32e-06	1.81e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—breast cancer	2.32e-06	1.81e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—breast cancer	2.31e-06	1.8e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—breast cancer	2.31e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—breast cancer	2.31e-06	1.8e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—breast cancer	2.31e-06	1.8e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—JUN—breast cancer	2.31e-06	1.79e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—COMT—breast cancer	2.3e-06	1.79e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—breast cancer	2.3e-06	1.79e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CTNNB1—breast cancer	2.29e-06	1.78e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTP1—breast cancer	2.29e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	2.29e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SRC—breast cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—breast cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—breast cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—breast cancer	2.27e-06	1.77e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—breast cancer	2.27e-06	1.76e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—breast cancer	2.26e-06	1.76e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—breast cancer	2.26e-06	1.76e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—JUN—breast cancer	2.26e-06	1.76e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMOX1—breast cancer	2.26e-06	1.76e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	2.26e-06	1.76e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ITPR1—breast cancer	2.25e-06	1.75e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—breast cancer	2.25e-06	1.75e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—breast cancer	2.24e-06	1.75e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	2.24e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	2.24e-06	1.74e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	2.24e-06	1.74e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—breast cancer	2.23e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CD—breast cancer	2.23e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—breast cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CAV1—breast cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—breast cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK8—breast cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—breast cancer	2.21e-06	1.72e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—breast cancer	2.21e-06	1.72e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—breast cancer	2.21e-06	1.72e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—breast cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—breast cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—breast cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—breast cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	2.19e-06	1.7e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—breast cancer	2.19e-06	1.7e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK8—breast cancer	2.18e-06	1.7e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	2.18e-06	1.7e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—breast cancer	2.18e-06	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—breast cancer	2.17e-06	1.69e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—breast cancer	2.17e-06	1.69e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCB1—breast cancer	2.17e-06	1.69e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—breast cancer	2.16e-06	1.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CASP3—breast cancer	2.16e-06	1.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—breast cancer	2.16e-06	1.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—breast cancer	2.15e-06	1.67e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—breast cancer	2.15e-06	1.67e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TGFB1—breast cancer	2.14e-06	1.67e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	2.14e-06	1.66e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—breast cancer	2.14e-06	1.66e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	2.13e-06	1.66e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TGFB1—breast cancer	2.13e-06	1.66e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TYMS—breast cancer	2.13e-06	1.66e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.12e-06	1.65e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—breast cancer	2.12e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NOS3—breast cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NCOR1—breast cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—breast cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—breast cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SRC—breast cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—breast cancer	2.1e-06	1.63e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—breast cancer	2.1e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JUN—breast cancer	2.1e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	2.09e-06	1.63e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—breast cancer	2.09e-06	1.62e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	2.08e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—breast cancer	2.08e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SRC—breast cancer	2.07e-06	1.61e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—breast cancer	2.05e-06	1.6e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—breast cancer	2.05e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—breast cancer	2.04e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—breast cancer	2.04e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TGFB1—breast cancer	2.04e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	2.03e-06	1.58e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—breast cancer	2.03e-06	1.58e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—breast cancer	2.03e-06	1.58e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SRC—breast cancer	2.03e-06	1.58e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CG—breast cancer	2.02e-06	1.57e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—breast cancer	2.02e-06	1.57e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—breast cancer	2.02e-06	1.57e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GPX1—breast cancer	2.01e-06	1.57e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—breast cancer	2e-06	1.56e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—breast cancer	2e-06	1.55e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—breast cancer	2e-06	1.55e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP1A1—breast cancer	1.99e-06	1.55e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—breast cancer	1.99e-06	1.55e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—breast cancer	1.98e-06	1.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	1.98e-06	1.54e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—breast cancer	1.98e-06	1.54e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.97e-06	1.54e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—breast cancer	1.97e-06	1.53e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—breast cancer	1.95e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.95e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CB—breast cancer	1.94e-06	1.51e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—breast cancer	1.94e-06	1.51e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—breast cancer	1.93e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—breast cancer	1.93e-06	1.5e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—breast cancer	1.91e-06	1.48e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—breast cancer	1.89e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	1.89e-06	1.47e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—breast cancer	1.88e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SRC—breast cancer	1.88e-06	1.46e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TGFB1—breast cancer	1.88e-06	1.46e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	1.87e-06	1.45e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—breast cancer	1.86e-06	1.45e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—breast cancer	1.85e-06	1.44e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—breast cancer	1.85e-06	1.44e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.85e-06	1.44e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—breast cancer	1.84e-06	1.43e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—breast cancer	1.84e-06	1.43e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	1.83e-06	1.43e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—breast cancer	1.83e-06	1.42e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—breast cancer	1.82e-06	1.42e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—breast cancer	1.82e-06	1.41e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—breast cancer	1.82e-06	1.41e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—breast cancer	1.81e-06	1.41e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	1.81e-06	1.41e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	1.81e-06	1.41e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CD—breast cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—breast cancer	1.76e-06	1.37e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—breast cancer	1.76e-06	1.37e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—breast cancer	1.75e-06	1.36e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.75e-06	1.36e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—breast cancer	1.74e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	1.74e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.73e-06	1.35e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAV1—breast cancer	1.72e-06	1.33e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—breast cancer	1.71e-06	1.33e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—breast cancer	1.71e-06	1.33e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—breast cancer	1.71e-06	1.33e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—breast cancer	1.69e-06	1.31e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—breast cancer	1.69e-06	1.31e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.68e-06	1.31e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NOS3—breast cancer	1.68e-06	1.31e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—breast cancer	1.68e-06	1.31e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—breast cancer	1.68e-06	1.31e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.68e-06	1.31e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—breast cancer	1.68e-06	1.3e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—breast cancer	1.67e-06	1.3e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.65e-06	1.28e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—breast cancer	1.61e-06	1.26e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—breast cancer	1.61e-06	1.25e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—breast cancer	1.61e-06	1.25e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—breast cancer	1.6e-06	1.24e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.57e-06	1.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CG—breast cancer	1.56e-06	1.22e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.56e-06	1.21e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CB—breast cancer	1.55e-06	1.21e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—breast cancer	1.55e-06	1.2e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.54e-06	1.2e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.54e-06	1.2e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—breast cancer	1.54e-06	1.2e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—breast cancer	1.54e-06	1.2e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—breast cancer	1.52e-06	1.18e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—breast cancer	1.49e-06	1.16e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—breast cancer	1.49e-06	1.16e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—breast cancer	1.48e-06	1.15e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—breast cancer	1.48e-06	1.15e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—breast cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.43e-06	1.11e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.43e-06	1.11e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—breast cancer	1.42e-06	1.1e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—breast cancer	1.42e-06	1.1e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—breast cancer	1.4e-06	1.09e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—breast cancer	1.39e-06	1.08e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—breast cancer	1.39e-06	1.08e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CD—breast cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—breast cancer	1.36e-06	1.06e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—breast cancer	1.36e-06	1.05e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—breast cancer	1.34e-06	1.04e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.33e-06	1.03e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—breast cancer	1.31e-06	1.02e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NOS3—breast cancer	1.3e-06	1.01e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—breast cancer	1.29e-06	1e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—breast cancer	1.27e-06	9.86e-06	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—breast cancer	1.26e-06	9.79e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CB—breast cancer	1.2e-06	9.31e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—breast cancer	1.19e-06	9.23e-06	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—breast cancer	1.18e-06	9.21e-06	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.17e-06	9.1e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—breast cancer	1.03e-06	8.05e-06	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—breast cancer	9.68e-07	7.53e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—breast cancer	9.46e-07	7.35e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—breast cancer	7.72e-07	6.01e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—breast cancer	7.3e-07	5.68e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—breast cancer	5.96e-07	4.64e-06	CbGpPWpGaD
